Neuroprotective effects depend on the model of focal ischemia following middle cerebral artery occlusion

European Journal of Pharmacology

Volumn 362, Issue 2-3, 1998, Pages 137-142

  Takamatsu, Hiroyuki ^a   Kondo, Kazunao ^a   Ikeda, Yasuhiko ^a   Umemura, Kazuo ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cerebral ischemia; Middle cerebral artery occlusion; Neuroprotection

Indexed keywords

4,7 DIHYDRO 3 ISOBUTYL 6 METHYL 4 (3 NITROPHENYL)THIENO[2,3 B]PYRIDINE 5 CARBOXYLIC ACID METHYL ESTER; 6 (1 IMIDAZOLYL) 7 NITRO 2,3 QUINOXALINEDIONE; ASCORBIC ACID DERIVATIVE; DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NORPHENAZONE; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; BRAIN ISCHEMIA; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE CEREBRAL ARTERY; NEUROPROTECTION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN EDEMA; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; ELECTROCOAGULATION; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; INTRACRANIAL EMBOLISM AND THROMBOSIS; MALE; NEUROPROTECTIVE AGENTS; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; TACROLIMUS;

EID: 0032409463     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00773-0     Document Type: Article

References (42)

1. Abe K., Yuki S., Kogure K. Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke. 19:1988;480-485.
2. Bullock R., Graham D.I., Swanson S., McCulloch J. Neuroprotective effect of the AMPA receptor antagonist LY-293558 in focal cerebral ischemia in the cat. J. Cereb. Blood Flow Metab. 14:1994;466-471.
3. Cao X., Phillis J.W. α-Phenyl-tert-butyl-nitrone reduces cortical infarct and edema in rats subjected to focal ischemia. Brain Res. 644:1994;267-272.
4. Chan P.H. Oxygen radicals in focal cerebral ischemia. Brain Pathol. 4:1994;59-65.
5. Chan P.H. Role of oxidants in ischemic brain damage. Stroke. 27:1996;1124-1129.
6. Genba T., Ninomiya M., Matsunaga K., Ueda M. Effects of a novel calcium antagonist, S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)-thieno[2,3-b] pyridine-5-carboxylate (S-312-d), on ischemic amino acid release and neuronal injury in stroke-prone spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 265:1993;463-467.
7. Gill R., Brazell C., Woodruff G.N., Kemp J.A. The neuroprotective action of dizocilpine (MK801) in the rat middle cerebral artery occlusion model of focal ischemia. Br. J. Pharmacol. 103:1991;2030-2036.
8. Hellstrom H.O., Wanhainen A., Valtysson H., Persson L., Hillered L. Effect of tirilazad mesylate given after permanent middle cerebral artery occlusion in rats. Acta Neurochir. 129:1994;188-192.
9. Kaku S., Umemura K., Mizuno A., Kawasaki T., Nakashima M. Evaluation of the disintegrin, triflavin, in a rat middle cerebral artery thrombosis model. Eur. J. Pharmacol. 321:1997;301-305.
10. Kawai H., Umemura K., Nakashima M. Effect of argatroban on microthrombi formation and brain damage in the rat middle cerebral artery thrombosis model. Jpn. J. Pharmacol. 69:1995;143-148.
11. Kawai H., Nakai H., Suga M., Yuki S., Watanabe T., Sato K. Effects of a novel free radical scavenger, MCI-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J. Pharmacol. Exp. Ther. 281:1997;1997.
12. Kuribayashi Y., Naritomi H., Sasaki M., Sawada T. Effects of L-ascorbic acid 2-[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyl-tridecyl)-2H-1- benzopyran-6yl-hydrogen phosphate] potassium salt on cerebral energy state and consciousness recovery following transient forebrain ischemia in gerbils. Arzneim.-Forsch./Drug Res. 44:1994;995-998.
13. Matsuno H., Uematsu T., Umemura K., Takiguchi Y., Asai Y., Nakashima M. A simple and reproducible cerebral thrombosis model in rats induced by a photochemical reaction and the effect of a plasminogen-plasminogen activator chimera in this model. J. Pharmacol. Toxicol. Methods. 29:1993;165-173.
14. 1. Neurosciences. 15:1989;371-376.
15. Morikawa E., Ginsberg M.D., Dietrich W.D., Duncan R.C., Busto R. Postischemic (S)-emopamil therapy ameliorates focal ischemic brain injury in rats. Stroke. 22:1991;355-360.
16. Nishi H., Watanabe T., Sakurai H., Yuki S., Ishibashi A. Effect of MCI-186 on brain edema in rats. Stroke. 20:1989;1236-1240.
17. Osborne K.A., Shigeno T., Balarsky A.-M., Ford I., McCulloch J., Teasdale G.M., Graham D.I. Quantitative assessment of early brain damage in a rat model of focal cerebral ischemia. J. Neurosurg. Psychiatry. 50:1987;402-410.
18. Park C.K., Hall E.D. Dose-dependence analysis of the effect of 21-aminosteroid tirilazad mesylate (U-74006F) upon neurological outcome and ischemic brain damage in permanent focal cerebral ischemia. Brain Res. 645:1994;157-163.
19. Park C.K., Nehls D.G., Graham D.I., Teasdale G.M., McCulloch J. Focal cerebral ischemia in cats: treatment with the glutamate antagonist MK-801 after induction of ischaemia. J. Cereb. Blood Flow Metab. 8:1998;757-762.
20. Park C.K., Nehls D.G., Graham D.I., Teasdale G.M., McCulloch J. The glutamate antagonist MK-801 reduces focal cerebral ischemic brain damage in the rat. Ann. Neurol. 24:1998;543-554.
21. Sauter A., Rudin M. Calcium antagonists reduce the extent of infarction in rat middle cerebral artery occlusion model as determined by quantitative magnetic resonance imaging. Stroke. 17:1986;1228-1234.
22. Schewe T. Molecular actions of Ebselen - an antiinflammatory antioxidant. Gen. Pharmacol. 26:1995;1153-1169.
23. Sharkey J., Butcher S.P. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischemia. Nature. 371:1994;336-339.
24. Swanson et al., 1990.
25. Takamatsu H., Kondo K., Ikeda Y., Umemura K. Hydroxyl radical generation after the third hour following ischemia contributes to brain damage. Eur. J. Pharmacol. 352:1998;165-169.
26. Takasago T., Peters E.E., Graham D.I., Masayasu H., Macrae I.M. Neuroprotective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion. Br. J. Pharmacol. 122:1997;1251-1256.
27. Takizawa S., Matsushima K., Fujita H., Nanri K., Ogawa S., Shinorara Y. A selective N-type calcium channel antagonist reduces extracellular glutamate release and infarct volume in focal ischemia. J. Cereb. Blood Flow Metab. 15:1995;611-618.
28. Tamura A., Graham D.I., McCulloch J., Teasdale G.M. Focal cerebral ischemia in the rats: 1. Description of technique and early neuropathological consequences following middle cerebral artery occlusion. J. Cereb. Blood Flow Metab. 1:1981;61-69.
29. Umemura K., Wada K., Uematsu T., Nakashima M. Evaluation of the combination of a tissue-type plasminogen activator, SUN9216, and a thromboxane A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model. Stroke. 24:1993;1077-1081.
30. Umemura K., Toshima Y., Nakashima M. Thrombolytic efficacy of a modified tissue-type plasminogen activator, SUN9216, in the rat middle cerebral artery thrombosis model. Eur. J. Pharmacol. 262:1994;27-31.
31. Umemura K., Wada K., Uematsu T., Mizuno A., Nakashima M. Effect of 21-aminosteroid lipid peroxidation inhibitor, U74006F in the rat middle cerebral artery occlusion model. Eur. J. Pharmacol. 251:1994;69-74.
32. Umemura K., Ishiye M., Kosuge K., Nakashima M. Effect of combination of a tissue-type plasminogen activator and an endothelin receptor antagonist, FR139317, in the rat cerebral infarction model. Eur. J. Pharmacol. 275:1995;17-21.
33. Umemura K., Kawai H., Ishihara H., Nakashima M. Inhibitory effect of clopidogrel, vapiprost and argatroban in the middle cerebral artery thrombosis in the rats. Jpn. J. Pharmacol. 67:1995;253-258.
34. Umemura K., Ishihara H., Nakashima M. Anti-platelet effects of clopidogrel in rat middle cerebral artery thrombosis model. Thrombosis Res. 80:1995;209-216.
35. Umemura K., Toshima Y., Asai F., Nakashima M. Effect of dietary docosahexaenoic acid enhances thrombolytic effect of tissue-type plasminogen activator in the rat middle cerebral artery thrombosis model. Thrombosis Res. 78:1995;379-387.
36. Umemura K., Gemba T., Mizuno A., Nakashima M. Inhibitory effect of MS-153 on elevated brain glutamate level induced by the rat middle cerebral artery occlusion. Stroke. 27:1996;1624-1628.
37. Umemura K., Shimakura A., Nakashima M. Neuroprotective effect of a novel AMPA antagonist, YM90K, in rat focal cerebral ischemia. Brain Res. 773:1997;61-65.
38. Watanabe T., Yuki S., Egawa M., Nishi H. Protective effect of MCI-186 on cerebral ischemia; Possible involvement of free radical scavenging and antioxidant actions. J. Pharmacol. Exp. Ther. 268:1994;1597-1604.
39. Watson B.D., Dietrich W.D., Busto R., Wachtel M.S., Ginsberg M.D. Induction of reproducible brain infarction by photochemically initiated thrombosis. Ann. Neurol. 17:1985;497-504.
40. Yatsugi S., Takahashi M., Kawasaki-Yatsugi S., Koshiya K., Sakamoto S., Uematsu D., Shimizu-Sasamata M. Neuroprotective effect of YM90K, a novel AMPA/kainate receptor antagonist, in focal cerebral ischemia in cats. J. Cereb. Blood Flow Metab. 16:1996;959-966.
41. Yang G.-Y., Betz A.L. Reperfusion-induced injury to the blood-brain barrier after middle cerebral artery occlusion in rats. Stroke. 25:1994;1658-1665.
42. Zembowicz A., Hatchett R.J., Radziszewski W., Gryglewski R.J. Inhibition of endothelial nitric oxide synthase by ebselen. Prevention by thiols suggests the inactivation by ebselen of a critical thiol essential for the catalytic activity of nitric oxide synthase. J. Pharmacol. Exp. Ther. 267:1993;1112-1117.